CRIG
ALNY icon

Charter Research & Investment Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Charter Research & Investment Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-585
Closed -$267K – 85
2025
Q3 		$267K Buy
+585
New +$238K 0.18% 73

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Charter Research & Investment Group's ALNY Position: Q4 2025 in Review

Charter Research & Investment Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 585 shares — an estimated $267K sold.

Charter Research & Investment Group first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $267K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Charter Research & Investment Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Charter Research & Investment Group sold 585 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $267K.
  • Charter Research & Investment Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Charter Research & Investment Group's Alnylam Pharmaceuticals position peaked at $267K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Charter Research & Investment Group's 13F filing for Q4 2025, filed 10 Feb 2026.